Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy

Executive Summary

Supported by robust data demonstrating knock-out response rates, Roche/Genentech’s Zelboraf (vemurafenib) has sailed through the FDA approval process, aided by a push from the agency.
Advertisement

Related Content

Targeted Drugs With Companion Dx May Draw Medicare NCD Interest – Phurrough
Yervoy Survival Data From First-Line Study Sealed The Deal For FDA Approval
Pfizer’s Crizotinib Eases Past FDA With Targeted Population
Personalized Medicine Coalition Proposes Policies For Next Iteration Of Genomics And Personalized Medicine Act
Deals Of The Week: General Dynamics/Vangent, Paladin/Labopharm, Human Genome Sciences/4-Antibody
Speedy Approval Of Roche's Zelboraf Puts Pressure On Bristol's Yervoy
Front-Line Of Melanoma Market Could Be Marketing Battle
Yervoy Cuts To The Head Of The Line: Ipilimumab Has Unrestricted Label
Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
The Lesson Of Jevtana: With A Survival Advantage, All Things Are Possible

Topics

Advertisement
UsernamePublicRestriction

Register

PS053707

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel